Powder: -20°C for 3 years | In solvent: -80°C for 1 year
The combination of Valproic acid with Coumarin-3-carboxylic acid (3-Carboxycoumarin) suppresses the proliferation and migration of lung cancer cells via EGFR/VEGFR2/c-Met-Akt-NF-κB signaling pathways; this combination may have a wide therapeutic and/or adjuvant therapeutic application in the treatment of lung cancer.
説明 | The combination of Valproic acid with Coumarin-3-carboxylic acid (3-Carboxycoumarin) suppresses the proliferation and migration of lung cancer cells via EGFR/VEGFR2/c-Met-Akt-NF-κB signaling pathways; this combination may have a wide therapeutic and/or adjuvant therapeutic application in the treatment of lung cancer. |
別名 | 3-Carboxycoumarin |
分子量 | 190.15 |
分子式 | C10H6O4 |
CAS No. | 531-81-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (262.95 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Coumarin-3-carboxylic acid 531-81-7 Angiogenesis Tyrosine Kinase/Adaptors VEGFR Coumarin 3 carboxylic acid Inhibitor 3-Carboxycoumarin inhibit Coumarin3carboxylic acid inhibitor